Last Night After The Close Piper Jaffary Raised CELG to $111 Target. Nice. Here's Link
January 8, 2013
05:39 EDT CELG Celgene upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Celgene citing positive data from the Apremilast Phase III psoriasis studies and the company's new 2017 guidance which implies 25% annual earnings growth. The firm raised its price target for shares to $111 from $86.